On April 23, 2021 Shanghai Junshi Biosciences reported that it stopped the Phase III trial of its anti-PD-1 candidate early because toripalimab met its survival endpoints at an interim review (Press release, Shanghai Junshi Bioscience, APR 23, 2021, View Source [SID1234578428]). Toripalimab was administered together with paclitaxel/cisplatin as a first-line treatment for patients with advanced esophageal squamous cell carcinoma. The combination met the pre-specified primary endpoints of Progression Free Survival and Overall Survival in a double-blind Phase III trial. Toripalimab is already approved for three other indications in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!